**Medical Clinics and Pharmacies**

The AstraZeneca/COVISHIELD vaccine doses will primarily be used to provide COVID-19 vaccines in doctors’ offices and pharmacies. Manitoba public health officials have developed guidance for the use of the AstraZeneca/Covishield vaccine. This information is being shared with providers and posted online to guide how appointments are booked once the vaccine is available in Manitoba clinics and pharmacies.

**Eligibility Criteria**

**March 29, 2021 -**[**Update on the use of the AstraZeneca/Covishield vaccine in Manitoba**](https://www.gov.mb.ca/covid19/vaccine/about.html#az-march29-update)

As part of the piloted roll-out of the AstraZeneca/Covishield, Manitobans aged 55 to 64 years (First Nations people aged 55 to 64) with a high-risk condition will be the first group eligible to receive the AstraZeneca/Covishield COVID-19 vaccine. These individuals are at increased risk of experiencing serious illness requiring hospitalization or death related to COVID-19.

Anyone who is ALREADY eligible for the Pfizer/Moderna COVID-19 vaccine (such as health care workers) and is aged 55 to 64 is also eligible to receive AstraZeneca/ Covishield COVID-19 vaccine.

However, anyone who has already received a dose of the Pfizer or Moderna mRNA vaccines must use the same product for their second dose, and should not receive the AstraZeneca/Covishield vaccine.

People with high-risk conditions (as determined by their doctor or pharmacist) will be prioritized, with those who have a condition in Priority List 1 being offered immunization before those with a condition in Priority List 2.

**Priority List 1:**

* Individuals with the following chronic health conditions:
	+ end stage renal disease undergoing hemodialysis **OR** peritoneal dialysis
	+ cirrhosis due to any cause **OR** portal hypertension
	+ heart failure (class III/IV ), ventricular assist device **OR** adult congenital heart disease stage C and D
	+ severe COPD, pulmonary hypertension, pulmonary fibrosis, interstitial lung disease **OR** cystic fibrosis
	+ history of cerebral vascular accident with residual deficits
	+ malignant hematologic disorders including leukemia and lymphoma **OR** clonal blood disorder
	+ malignant neoplasms (solid tissue) who will receive or are currently receiving immunosuppressive therapy including chemotherapy
	+ severe obesity (BMI ≥ 40)
	+ receiving one or more of the following immunosuppressive therapies: B cell therapies (e.g., rituximab, ocrelizumab), cyclophosphamide, alemtuzumab, calcineurin inhibitors, chronic dose prednisone >=20mg/day, mycophenolate, sulfasalazine and JAK inhibitors (e.g., tofacitinib)
	+ solid organ or hematopoietic stem cell transplant (candidate or recipient)
	+ trisomy 21 (Down syndrome)
	+ asplenia or hyposplenism (including sickle cell disease)
* Individuals receiving home care ≥ 4 times/week **OR** receive 24/7 support from Community Living Disability Services.

**Priority List 2:**

* Individuals with the following chronic health conditions:
	+ Chronic cardiovascular disease including heart failure (class I/II), coronary artery disease, malignant tachyarrythmia **OR** cardiomyopathies
	+ chronic liver disease
	+ chronic neurologic **OR** neurodevelopmental conditions including cerebral palsy, Parkinson’s disease, multiple sclerosis, ALS **OR** dementia (including Alzheimer’s disease)
	+ chronic pulmonary disease including COPD **OR** severe and/or uncontrolled asthma
	+ chronic renal disease
	+ HIV (CD4 cell count ≥ 200 x 106/L and CD4 percentage ≥ 15%)
	+ severe systemic autoimmune disorders (e.g., systemic lupus erythematosus, scleroderma, myocarditis, rheumatoid arthritis)
	+ type 1 or 2 diabetes mellitus (poorly controlled and/or with complications)
	+ active tuberculosis (current or previous) **OR** current latent tuberculosis (LTBI)
	+ receiving [immunosuppressing therapy](https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-8-immunization-immunocompromised-persons.html#a25)
* Individuals receiving homecare ≤ 3 times/week **OR** any level of Community Living Disability Services supports (or as per family physician determination of equivalent levels of family support).
* Household contacts of individuals with Priority 1 chronic health conditions **OR** designated support person(s) for personal care home residents (in the authorized age category).